People · Operator
Named in public records as an officer, director or promoter · active 2009–2013 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Somaxon Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $6.0M | $185.8M | 2009 |
| OrPro Therapeutics, Inc. | — | Biotechnology | Seed | $3.7M | $103.8M | 2013 |
Jeffrey W. Raser at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey W. Raser on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David F Hale | 1 | 16 |
| Cam L. Garner | 1 | 11 |
| Kurt Von Emster | 1 | 6 |
| Jesse I. Treu | 1 | 5 |
| Richard W. Pascoe | 1 | 4 |
| Kurt C. Wheeler | 1 | 3 |
| Erle T. Mast | 1 | 3 |
| Thomas G. Wiggans | 1 | 3 |
| Michael L. Eagle | 1 | 2 |
| Mary Jacqueline Johnson | 1 | 2 |
| James W. Weil | 1 | 1 |
| Peter B. Heifetz, Ph.D. | 1 | 1 |
| Brian T. Dorsey | 1 | 1 |
| Terrell A. Cobb | 1 | 1 |
| Matthew W. Onaitis | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.